NCI-2025-03305

A Multicenter, Open-label, First-in-Human Study of TYRA-430 in Advanced HepatocellularCarcinoma and Other Solid Tumors with Activating FGF/FGFR pathway aberrations (SURF-431)

The SURF-431 study is a multicenter, open-label, first-in-human Phase 1 trial testing a new investigational drug called TYRA-430 in people with advanced hepatocellular carcinoma (HCC)—a type of liver cancer—and other solid tumors that have specific genetic changes in the FGF/FGFR signaling pathway. The FGF/FGFR pathway (fibroblast growth factor and its receptor family) helps regulate cell growth and repair. However, in some cancers, mutations or other abnormalities in this pathway cause cells to grow uncontrollably. TYRA-430 is designed to block abnormal FGFR activity, potentially slowing or stopping cancer growth. The ultimate goal is to determine whether TYRA-430 could become a new targeted therapy option for patients with advanced cancers linked to FGF/FGFR pathway alterations, especially those who have few or no remaining treatment options.

Open Label: Patients know which treatments are being given to them

Phase 1: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

Advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

Mutations: Mutation is an alteration in the genetic material of a cell or a virus that can be inherited by its descendants

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06915753

Clinical Trial Site: Columbia

To see all available clinical trials click here.